A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer

Summary

This study will evaluate efficacy, safety and tolerability of Avastin versus placebo added to a chemotherapeutic regimen in patients with metastatic pancreatic cancer. The anticipated time of study treatment is until confirmed evidence of disease progression, and the target sample size is 500+ individuals.

Timeline

Start

2005-07

Primary completion

2008-10

Completion

2008-10

Outcome

Missed primary endpoint

registry analysis (superiority or other test); Bevacizumab + Gemcitabine + Erlotinib vs Placebo + Gemcitabine + Erlotinib; p = 0.2087; Hazard Ratio (HR) 0.89 (95% CI 0.74 to 1.07); Log Rank NCT01214720 ↗

Drugs

Indications